A murine model of cutaneous aspergillosis for evaluation of biomaterials‐based local delivery therapies2. Issue 9 (7th April 2019)

• Record Type: Journal Article
• Authors: Tatara, Alexander M.; Watson, Emma; Albert, Nathaniel D.; Kontoyiannis, Panayiotis D.; Kontoyiannis, Dimitrios P.; Mikos, Antonios G.
• Is Part Of: Journal of biomedical materials research. Volume 107:Issue 9(2019)
• Page Start: 1867
• Page End: 1874
• Publication Date: 2019-04-07
• Subjects: cutaneous -- fungi -- Aspergillus -- biomaterials -- drug delivery; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.a.36671
• Languages: English
• ISSNs: 1549-3296

Abstract

Abstract: Cutaneous fungal infection is a challenging condition to treat that primarily afflicts immunocompromised patients. Local antifungal therapy may permit the delivery of high concentrations of antifungals directly to wounds while minimizing systemic toxicities. However, the field currently lacks suitable in vivo models. Therefore, a large cutaneous wound was created in immunosuppressed mice and inoculated with Aspergillus fumigatus . We fabricated biodegradable polymer microparticles (MPs) that were capable of locally delivering antifungal and characterized in vitro release kinetics. We compared wound bed size, fungal burden, and histological presence of fungi in mice treated with antifungal‐loaded MPs. Mice with a cutaneous defect but no infection, mice with infected cutaneous defect but no treatment, and infected mice treated with blank MPs were used as controls. Infection of large wounds inhibited healing and resulted in tissue invasion in an inoculum‐dependent manner. MPs were capable of releasing antifungals at concentrations above A. fumigatus Minimum Inhibitory Concentration (MIC) for at least 6 days. Wounds treated with MPs had significantly decreased size compared with no treatment (64.2% vs. 19.4% wound reduction, p = 0.002) and were not significantly different from uninfected controls (64.2% vs. 58.1%, p = 0.497). This murine model may serve to better understand cutaneous fungal infection and evaluate local biomaterials‐based therapies. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 1867–1874, 2019.